HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Looks To Future After Difficult 2019

Executive Summary

With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.

You may also be interested in...



Tighter Controls For Pseudoephedrine OTCs In France

Popular OTC drugs from J&J, Sanofi and Reckitt Benckiser are among those affected by new rules for the dispensing of pseudoephedrine-containing products in France following a spike in adverse events related to misuse of oral vasoconstrictors.

French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.

OTC Zantac And Private Label Ranitidine Numerous In FDA Recall Updates

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

Related Content

Topics

UsernamePublicRestriction

Register

RS149673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel